Laurence Bouillet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1554717/publications.pdf

Version: 2024-02-01

113 papers	5,238 citations	101496 36 h-index	91828 69 g-index
138 all docs	138 docs citations	138 times ranked	2551 citing authors

#	Article	IF	Citations
1	Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. Journal of Allergy and Clinical Immunology, 2004, 114, S51-S131.	1.5	582
2	Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema. New England Journal of Medicine, 2010, 363, 532-541.	13.9	477
3	2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy, Asthma and Clinical Immunology, 2010, 6, 24.	0.9	443
4	International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. Journal of Allergy and Clinical Immunology, 2012, 129, 308-320.	1.5	207
5	Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Annals of Allergy, Asthma and Immunology, 2008, 100, S30-S40.	0.5	181
6	Efficacy of anti-TNF alpha in severe and/or refractory BehÃ§et's disease: Multicenter study of 124 patients. Journal of Autoimmunity, 2015, 62, 67-74.	3.0	178
7	The international WAO/EAACI guideline for the management of hereditary angioedemaâ€"The 2021 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1961-1990.	2.7	153
8	HAE international home therapy consensus document. Allergy, Asthma and Clinical Immunology, 2010, 6, 22.	0.9	149
9	Disease expression in women with hereditary angioedema. American Journal of Obstetrics and Gynecology, 2008, 199, 484.e1-484.e4.	0.7	134
10	Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment. PLoS ONE, 2013, 8, e53773.	1.1	113
11	Metallopeptidase activities in hereditary angioedema: Effect of androgen prophylaxis on plasma aminopeptidase P. Journal of Allergy and Clinical Immunology, 2008, 121, 429-433.	1.5	104
12	Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Annals of Allergy, Asthma and Immunology, 2013, 111, 290-294.	0.5	88
13	Type III hereditary angioâ€oedema: clinical and biological features in a French cohort. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1331-1336.	2.7	87
14	Female Infertility and Serum Auto-antibodies: a Systematic Review. Clinical Reviews in Allergy and Immunology, 2017, 53, 78-86.	2.9	87
15	Diagnosis and Treatment of Bradykinin-Mediated Angioedema: Outcomes from an Angioedema Expert Consensus Meeting. International Archives of Allergy and Immunology, 2014, 165, 119-127.	0.9	83
16	Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Annals of Allergy, Asthma and Immunology, 2016, 117, 394-398.	0.5	78
17	Benefits of progestin contraception in nonâ€allergic angioedema. Clinical and Experimental Allergy, 2013, 43, 475-482.	1.4	70
18	BRADYKININ RECEPTOR 2 ANTAGONIST (ICATIBANT) FOR HEREDITARY ANGIOEDEMA TYPE III ATTACKS. Annals of Allergy, Asthma and Immunology, 2009, 103, 448.	0.5	68

#	Article	IF	Citations
19	A nationwide study of acquired C1-inhibitor deficiency in France. Medicine (United States), 2016, 95, e4363.	0.4	64
20	Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clinical and Experimental Immunology, 2014, 178, 112-117.	1.1	58
21	Tocilizumab in severe and refractory Behcetâ€™s disease: Four cases and literature review. Seminars in Arthritis and Rheumatism, 2016, 45, 733-737.	1.6	58
22	The global impact of the COVIDâ€19 pandemic on the management and course of chronic urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 816-830.	2.7	58
23	Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema. Journal of Investigational Allergology and Clinical Immunology, 2016, 26, 383-386.	0.6	57
24	A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. British Journal of Dermatology, 2007, 156, 1063-1065.	1.4	55
25	Hereditary angioedema: Key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation. Journal of Allergy and Clinical Immunology, 2011, 128, 232-234.	1.5	54
26	Helicobacter pylori Infection as a Triggering Factor of Attacks in Patients with Hereditary Angioedema. Helicobacter, 2007, 12, 251-257.	1.6	53
27	Hereditary angioedema in women. Allergy, Asthma and Clinical Immunology, 2010, 6, 17.	0.9	53
28	Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clinical and Experimental Immunology, 2012, 168, 303-307.	1.1	51
29	Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 464-473.e4.	2.0	48
30	Angioedema and Oral Contraception. Dermatology, 2003, 206, 106-109.	0.9	45
31	Hereditary Angioedema in Women. Immunology and Allergy Clinics of North America, 2013, 33, 505-511.	0.7	45
32	International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 901-911.	2.0	43
33	Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema. Clinical and Experimental Immunology, 2016, 185, 332-337.	1.1	42
34	Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: Three additional French families. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2237-2239.	2.7	40
35	Hepatitis E and neuralgic amyotrophy: Five cases and review of literature. Journal of Clinical Virology, 2015, 69, 156-164.	1.6	38
36	Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212705.	0.5	38

#	Article	IF	Citations
37	Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals. International Archives of Allergy and Immunology, 2015, 167, 21-28.	0.9	37
38	The international WAO/EAACI guideline for the management of hereditary angioedema â€“ The 2021 revision and update. World Allergy Organization Journal, 2022, 15, 100627.	1.6	37
39	Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The <scp>OPuS</scp>â€2Âstudy. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1871-1880.	2.7	31
40	Angioedema Triggered by Medication Blocking the Renin/Angiotensin System: Retrospective Study Using the French National Pharmacovigilance Database. Journal of Clinical Immunology, 2016, 36, 95-102.	2.0	29
41	Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey. Clinical and Translational Allergy, 2018, 8, 42.	1.4	29
42	Definition, aims, and implementation of GA²LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2115-2123.	2.7	29
43	Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey. Clinical and Experimental Immunology, 2017, 188, 148-153.	1.1	28
44	Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant. Immunity, Inflammation and Disease, 2017, 5, 29-36.	1.3	27
45	Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (BerinertÂ®) in a French cohort. European Journal of Dermatology, 2017, 27, 155-159.	0.3	24
46	Evidence for Post-Translational Processing of Vascular Endothelial (VE)-Cadherin in Brain Tumors: Towards a Candidate Biomarker. PLoS ONE, 2013, 8, e80056.	1.1	23
47	Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1â€antihistamine treatment: results of the phase <scp>IV</scp> openâ€label <scp>SUNRISE</scp> study. British Journal of Dermatology, 2019, 180, 56-66.	1.4	22
48	The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1214-1222.	1.3	21
49	Exogenous hormones and hereditary angioedema. International Immunopharmacology, 2020, 78, 106080.	1.7	21
50	Myasthenia Gravis Associated with Acute Hepatitis E Infection in Immunocompetent Woman. Emerging Infectious Diseases, 2014, 20, 908-910.	2.0	20
51	VE-cadherin Y685F knock-in mouse is sensitive to vascular permeability in recurrent angiogenic organs. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H455-H463.	1.5	19
52	Analysis of characteristics associated with reinjection of icatibant: Results from the Icatibant Outcome Survey. Allergy and Asthma Proceedings, 2015, 36, 399-406.	1.0	19
53	Hereditary angioedema and lupus: A French retrospective study and literature review. Autoimmunity Reviews, 2015, 14, 564-568.	2.5	19
54	Idiopathic Angioedema: Current Challenges . Journal of Asthma and Allergy, 2020, Volume 13, 137-144.	1.5	18

#	Article	IF	Citations
55	Auto-antibodies to vascular endothelial cadherin in humans: association with autoimmune diseases. Laboratory Investigation, 2013, 93, 1194-1202.	1.7	17
56	Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants. Frontiers in Medicine, 2020, 7, 358.	1.2	17
57	Longâ€term safety of icatibant treatment of patients with angioedema in realâ€world clinical practice. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 994-998.	2.7	16
58	Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients. Journal of Clinical Immunology, 2017, 37, 80-84.	2.0	16
59	Bradykinin mechanism is the main responsible for death by isolated asphyxiating angioedema in France. Clinical and Experimental Allergy, 2018, 49, 252-254.	1.4	16
60	Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema. Clinical Reviews in Allergy and Immunology, 2021, 61, 84-97.	2.9	16
61	Idiopathic histaminergic angioedema without wheals: a case series of 31 patients. Clinical and Experimental Immunology, 2016, 185, 81-85.	1.1	15
62	Effects of pregnancy on chronic urticaria: Results of the PREGâ€CU UCARE study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3133-3144.	2.7	15
63	Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. Annals of Allergy, Asthma and Immunology, 2015, 114, 499-503.	0.5	14
64	Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey. Allergy, Asthma and Clinical Immunology, 2017, 13, 31.	0.9	14
65	Update on bradykinin-mediated angioedema in 2020. Therapie, 2020, 75, 195-205.	0.6	13
66	Severe acute neurological symptoms related to proton pump inhibitors induced hypomagnesemia responsible for profound hypoparathyroidism with hypocalcemia. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, e103-e105.	0.7	12
67	Recurrent angioedema: diagnosis strategy and biological aspects. European Journal of Dermatology, 2014, 24, 293-296.	0.3	12
68	COVIDâ€19 as a trigger of acute attacks in people with hereditary angioedema. Clinical and Experimental Allergy, 2021, 51, 947-950.	1.4	12
69	Biological autoimmunity screening in hepatitis C patients by anti-HepG2 lysate and anti-heat shock protein 70.1 autoantibodies. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 137-146.	1.3	11
70	Icatibant in hereditary angioedema: news and challenges. Expert Review of Clinical Immunology, 2011, 7, 267-272.	1.3	11
71	An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II. Core Evidence, 2012, 7, 105.	4.7	11
72	Analysis of autofluorescence pattern in birdshot chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1333-1339.	1.0	10

#	Article	IF	Citations
73	Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey. Clinical and Translational Allergy, 2019, 9, 37.	1.4	10
74	Five-Year Trends in Multifocal Electroretinogram for Patients With Birdshot Chorioretinopathy. American Journal of Ophthalmology, 2019, 200, 138-149.	1.7	10
75	Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitorâ€“induced angioedema: A disproportionality analysis of the WHO pharmacovigilance database. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2406-2408.e1.	2.0	10
76	Dynamic phosphorylation of VE-cadherin Y685 throughout mouse estrous cycle in ovary and uterus. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H448-H454.	1.5	9
77	Serum amyloid A as a marker of disease activity in Giant cell arteritis. Autoimmunity Reviews, 2020, 19, 102428.	2.5	9
78	VE-cadherin, a potential marker for endothelial cell activation during hereditary angioedema attacks. Journal of Allergy and Clinical Immunology, 2014, 134, 241.	1.5	8
79	BIOBRAD Study: The Search for Biomarkers of Bradykinin-Mediated Angio-Oedema Attacks. International Archives of Allergy and Immunology, 2016, 170, 108-114.	0.9	8
80	Screening of hepatitis E in patients presenting for acute neurological disorders. Journal of Infection and Public Health, 2020, 13, 1047-1050.	1.9	8
81	Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2490-2491.	2.0	8
82	Hormonal Effects on Urticaria and Angioedema Conditions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2209-2219.	2.0	8
83	Efficacy of icatibant treatment in patients with hereditary angio-oedema type I resistant to treatment with C1 inhibitor concentrate. British Journal of Dermatology, 2011, 164, 1406-1407.	1.4	6
84	Bradykinin-mediated angioedema. European Journal of Emergency Medicine, 2016, 23, 219-223.	0.5	6
85	Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster-Randomized Controlled Trial. Annals of Emergency Medicine, 2018, 72, 194-203.e1.	0.3	6
86	Hereditary angioedema, emergency management of attacks by a call center. European Journal of Internal Medicine, 2019, 67, 42-46.	1.0	6
87	Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial. Trials, 2016, 17, 225.	0.7	5
88	Normal PAI-2 level in French FXII-HAE patients. Journal of Allergy and Clinical Immunology, 2017, 139, 1719-1720.	1.5	5
89	Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series. Allergy, Asthma and Clinical Immunology, 2022, 18, 4.	0.9	5
90	Glucocorticoids for acute urticaria: study protocol for a double-blind non-inferiority randomised controlled trial. BMJ Open, 2019, 9, e027431.	0.8	4

#	Article	IF	Citations
91	Letter to the Editor: Protein phosphatase 1 subunit Ppp1r15a/GADD34 is overexpressed in systemic lupus erythematosus and related to the expression of type I interferon response genes. Autoimmunity Reviews, 2019, 18, 211-213.	2.5	4
92	Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women. Journal of Clinical Immunology, 2021, 41, 163-170.	2.0	4
93	Contribution of anti-Hsp70.1 IgG Antibody Levels to the Diagnostic Certainty of Clinically Suspected Ocular Toxoplasmosis. , 2010, 51, 5530.		3
94	Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study. Clinical and Translational Allergy, 2018, 8, 11.	1.4	3
95	Variability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2421-2430.	1.3	3
96	Progestins are Efficient Agents in Estrogen-sensitive Nonhistaminic Angioedema. American Journal of Medicine, 2014, 127, e7.	0.6	2
97	Monitoring of visual field over 6Âmonths after active ocular toxoplasmosis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 1481-1488.	1.0	2
98	Tolerance and efficacy of anti-TNF currently used for severe non-infectious uveitis. Autoimmunity Reviews, 2021, 20, 102752.	2.5	2
99	Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation. Annals of Allergy, Asthma and Immunology, 2021, 127, 391-392.	0.5	2
100	Severe Pneumocystis jirovecii pneumonia in an idiopathic CD4+ lymphocytopenia patient: case report and review of the literature. JMM Case Reports, 2014, 1, e003434.	1.3	2
101	Effective Antiâ€“SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1356-1364.e2.	2.0	2
102	Angioedemas hereditarios y adquiridos. EMC - DermatologÃa, 2016, 50, 1-6.	0.1	1
103	Guillain-BarrÃ© syndrome in AIDS patient secondary to an acute and confirmed hepatitis C virus. Presse Medicale, 2019, 48, 981-982.	0.8	1
104	Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France. Allergy, Asthma and Clinical Immunology, 2022, 18, 30.	0.9	1
105	Les angiÅ“dÃ¨me hÃ©rÃ©ditaires de type IIIÂ: nouvelle maladie ou nouveau diagnosticÂ?. Revue Francaise D'allergologie Et D'immunologie Clinique, 2008, 48, 155-158.	0.1	0
106	AngiÅ“dÃ¨me rÃ©currentÂ: dÃ©marche diagnostique et place de la biologie. Revue Francaise D'allergologie, 2013, 53, 528-532.	0.1	0
107	Les angiÅ“dÃ¨mes bradykiniquesÂ: stratÃ©gie thÃ©rapeutique en 2013. Revue Francaise D'allergologie, 2013, 53, 195-200.	0.1	0
108	SAT0351â€…Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study OF34 Patients. Annals of the Rheumatic Diseases, 2016, 75, 794.1-794.	0.5	0

#	Article	IF	Citations
109	Efficacy of C1 inhibitor concentrate in hereditary angioedema with C1 inhibitor deficiency. Annals of Allergy, Asthma and Immunology, 2018, 121, 506-508.	0.5	0
110	Mast cell activation diseases and chronic spontaneous urticaria: Common points and differences. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1121-1123.e1.	2.0	0
111	Prospective study of serum and aqueous humour antiâ€Hsp70.1 IgG antibody levels in ocular toxoplasmosis. Parasite Immunology, 2020, 42, e12771.	0.7	0
112	Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria. European Journal of Dermatology, 2021, 31, 86-87.	0.3	0
113	Angioedema. , 2021, , 133-147.		0